Karbicombi

Hydrochlorothiazide and Candesartan cilexetil, the active ingredients in Karbicombi, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for oral use. They treat hypertension in adult patients by reducing blood pressure through combined diuretic and vasodilatory effects. The combination is indicated for the management of high blood pressure and is often used when monotherapy does not achieve target levels.

GNH USA supplies Karbicombi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global health programs.

Karbicombi is used to lower elevated blood pressure by acting on the renin‑angiotensin system and promoting diuresis. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Stage 1 hypertension: helps achieve target blood pressure when lifestyle measures are insufficient. - Stage 2 hypertension: provides additional control for patients requiring more than one antihypertensive agent.

Like all antihypertensive agents, Karbicombi may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: light‑headedness especially after standing. - Headache: mild to moderate intensity. - Increased urination: due to diuretic effect. - Electrolyte imbalance: such as low potassium or sodium. - Fatigue: general tiredness. - Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Angioedema: swelling of face, lips, tongue or throat. - Acute kidney injury: sudden decline in renal function. - Severe hypotension: dangerously low blood pressure. - Pancreatitis: inflammation of the pancreas.

When prescribing Karbicombi, clinicians should consider several safety precautions to minimize risk. - Monitor electrolytes: check sodium and potassium levels regularly. - Assess renal function: evaluate creatinine and eGFR before and during therapy. - Use caution in elderly: increased sensitivity to blood pressure changes. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Contraindicated in severe renal impairment: do not use in patients with markedly reduced kidney function. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Karbicombi can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: combined use may cause excessive potassium rise and renal dysfunction. - Aliskiren: concurrent use increases risk of hypotension and kidney injury. - Potassium‑sparing diuretics or supplements: may lead to dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can reduce antihypertensive effect and affect kidney function. - Other antihypertensives: may enhance blood pressure lowering, requiring dose adjustment.